How Will the Rise in Antibiotic Resistance Shape the U.S. Prescribing and Reimbursement Environment for Novel Antibiotics? Although antibiotics from several drug classes are available to treat…
A Survey of Nephrologists and Interviews with Payers in the EU5 Renal anemia and hyperphosphatemia, or elevated serum phosphorous, are two primary complications of chronic kidney disease (CKD)…
How Does Cost Versus Dosing Impact Prescriber Preferences and Payer Policy? Agents that target vascular endothelial growth factor (VEGF) have expanded the treatment armamentarium in Brazil and…
Payer and Physician Receptivity to Oral HIF-PH Inhibitors and Other Novel Treatments: Which Emerging Drugs Excite Them? Renal anemia is one of the primary complications of chronic kidney disease (…
Cancer immunotherapy is one of the most exciting fields of research in oncology. Successful drug development in this space offers a highly lucrative opportunity for drug developers. Most excitement…
In a Market of Entrenched, Effective, and Mostly Generic Therapies, Where Do Physicians and Payers Identify Areas for Differentiation? The prevalence of Parkinson’s disease (PD) will approach 3…
Compared with Current and Emerging Non-Insulin Therapies, Does Metformin’s Clinical Profile Justify Its Dominant Position in Recommended Treatment Guidelines? Affecting 30 million people in the…
How Will U.S. Payer and Prescriber Attitudes Shape This Competitive Market? The treatment of non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)…
This report leverages physician insights, as well as a year’s worth of patient chart data, to provide the most up-to-date information about dialysis patient care in the EU5, including patient…
Which Attributes, in the Eyes of Oncologists and Payers, Will Allow Emerging Therapies to Gain Traction in a Market Experiencing Generic Erosion? Drug development for advanced/metastatic, hormone-…
LaunchTrends: Keytruda (Wave 2) is the second in a series of syndicated reports designed to track the physician perception, uptake, and competitive environment of the malignant melanoma drug…
How Are Novel Therapies Differentiated from Current Treatment Options in This Highly Genericized Market? Acute heart failure (AHF) is one of the leading causes of hospitalization in the developed…
TreatmentTrends®: Breast Cancer Q2 2015 (US) in the first in a series of reports that examine current trends in the management of advanced/metastatic breast cancer from the perspective of medical…
Securing Market Share and Payer Acceptance in Increasingly Crowded and Segmented Markets in Brazil and Mexico Small molecule therapies offer specific targeting of the aberrant cellular signaling…
LaunchTrends: Ibrance (Wave 1) is the first in a series of syndicated reports designed to track physician perception, uptake, and competitive environment regarding the newly launched breast cancer…
